US EditionINOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
- INOVIO announced promising interim results from a Phase 1 trial evaluating DMAbs for COVID-19, showing durable antibody production in 100% of participants after 72 weeks.
- No anti-drug antibodies were detected in the trial, addressing challenges faced by other gene-based therapies, according to INOVIO's research.
- Side effects from the DMAb treatment were mainly mild and included temporary injection site reactions, as noted in the final report.
- The trial is led by The Wistar Institute, in collaboration with INOVIO, AstraZeneca, and the University of Pennsylvania.
49 Articles
49 Articles
Kingsport Times-News
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepointNo anti-drug antibodies (ADA): no immune rejection of the DMAbs was detected across ~1,000 blood samples, unlike other gene-based antibody…
INOVIO’s Covid-19 dMAb maintains in-vivo detection in 100% participants
Results saw all 24 healthy volunteers who made it to the 72-week mark still had effective levels of dMAb in their systems.The post INOVIO’s Covid-19 dMAb maintains in-vivo detection in 100% participants appeared first on Clinical Trials Arena.
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19 - PressReach
Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint No anti-drug antibodies (ADA): no immune rejection of the DMAbs was detected across ~1,000 blood samples, unlike other gene-based antibody delivery approaches where ADA formation has been a challenge Well-tolerated: most common side effects were mild, temporary injection site reactions such as pain and red…
Coverage Details
Bias Distribution
- 75% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
